This pilot study aimed to assess the efficacy in treating sexually active menopausal patients who had dyspareunia related to vulvovaginal atrophy (VVA).
Materials and Methods
The intensity of VVA symptoms was recorded for each patient. Patients were administered the Short Form 12 (SF-12) and the female sexual function index (FSFI) to assess quality of life and sexual function, respectively. An objective evaluation of female urogenital health was performed using the Gloria Bachman Vaginal Health Index (VHI).
Results
At 12-week follow-up, the laser treatment was efficacious in improving dyspareunia in 100% of patients included in the study (n = 15). The intensity of dyspareunia significantly decreased from baseline (8.7 ± 1.0) to 12-week follow-up (2.2 ± 1.0; p<0.001). In addition, all other VVA symptoms significantly ameliorated at the same follow-up. Furthermore, after the treatment, a significant improvement in quality of life (QoL) and sexual function were shown.
Conclusions
This pilot study demonstrated that treatment with the microablative fractional CO2 laser of patients with dyspareunia related to VVA was efficacious at 12-week follow-up.
Get full access to this article
View all access options for this article.
References
1.
van der LaakJ.A., de BieL.M., de LeeuwH., de WildeP.C., HanselaarA.G.The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol.2002; 55(6): 446–451.
2.
BachmannG.A., ChengR.J., RovnerE.Vulvovaginal complaints. In: LoboR.A., ed. Treatment of the postmenopausal woman: basic and clinical aspects.3rd ed.Burlington, MA: Academic Press; 2007: 263–270.
3.
SantoroN., KomiJ.Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med.2009; 6(8): 2133–2142.
4.
PastoreL.M., CarterR.A., HulkaB.S., WellsE.Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas.2004; 49(4): 292–303.
5.
Barnabei VM, Cochrane BB, Aragaki AK, et al; Women's Health Initiative Investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol.2005; 105(5 Pt 1): 1063–1073.
6.
NappiR.E., Kokot-KierepaM.Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas.2010; 67(3): 233–238.
7.
NappiR.E., Kokot-KierepaM.Vaginal Health: Insights, Views & Attitudes (VIVA): results from an international survey. Climacteric.2012; 15(1): 36–44.
8.
CummingG.P., CurrieH.D., MoncurR., LeeA.J.Web-based survey on the effect of menopause on women's libido in a computer-literate population. Menopause Int.2009; 15(1): 8–12.
9.
CummingG.P., HeraldJ., MoncurR., CurrieH., LeeA.J.Women's attitudes to hormone replacement therapy, alternative therapy and sexual health: a web-based survey. Menopause Int.2007; 13(2): 79–83.
10.
LevineK.B., WilliamsR.E., HartmannK.E.Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause.2008; 15(4 Pt 1): 661–666.
11.
NappiR.E., KingsbergS., MaamariR., SimonJ.The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) survey: implications of vaginal discomfort in post-menopausal women and in male partners. J Sex Med.2013; 10(9): 2232–2241.
12.
LindauS.T., SchummL.P., LaumannE.O., LevinsonW., O'MuircheartaighC.A., WaiteL.J.A study of sexuality and health among older adults in the United States. N Engl J Med.2007; 357(8): 762–774.
13.
ParishS.J., NappiR.E., KrychmanM.L.. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health.2013; 5: 437–447.
14.
The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause.2013; 20(9): 888–902 [quiz: 903-904].
15.
SucklingJ., LethabyA., KennedyR.Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev.2006; (4): CD001500.
16.
ShulmanL.P., PortmanD.J., LeeW.C.. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice. J Womens Health (Larchmt).2008; 17(4): 569–578.
17.
OngM.W., BashirS.J.Fractional laser resurfacing for acne scars: a review. Br J Dermatol.2012; 166(6): 1160–1169.
18.
TierneyE.P., HankeC.W.Fractionated carbon dioxide laser treatment of photoaging: prospective study in 45 patients and review of the literature. Dermatol Surg.2011; 37(9): 1279–1290.
19.
TierneyE.P., HankeC.W.Ablative fractionated CO2, laser resurfacing for the neck: prospective study and review of the literature. J Drugs Dermatol.2009; 8(8): 723–731.
20.
PetersonJ.D., GoldmanM.P.Rejuvenation of the aging chest: a review and our experience. Dermatol Surg.2011; 37(5): 555–571.
21.
SalvatoreS., DigesuG., SiestoG.. Vaginal collagen remodelling after fractional carbon dioxide laser surgery [abstract 233]. Presented at the annual meeting of the International Continence Society, Glasgow, United Kingdom, August-September 2011.
22.
SalvatoreS., NappiR.E., ZerbinatiN.. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric.2014; Jun 5: 1–7. [Epub ahead of print]
23.
BumpR.C., MattiassonA., BøK.. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol.1996; 175(1): 10–17.
24.
BachmannG.Urogenital ageing: an old problem newly recognized. Maturitas.1995; 22(Suppl): S1–S5.
25.
WareJ.Jr., KosinskiM., KellerS.D.A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care.1996; 34(3): 220–233.
26.
RosenR., BrownC., HeimanJ.. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther.2000; 26(2): 191–208.
27.
NappiR.E., AlbaniF., VaccaroP.. Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice. Gynecol Endocrinol.2008; 24(4): 214–219.
28.
WiegelM., MestonC., RosenR.The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther.2005; 31(1): 1–20.
29.
US Census Bureau. Statistical Abstract of the United States: 2012. Table 7. Resident population by sex and age: 1980 to 2010. Washington, DC: US Census Bureau; 2011. Available from: http://www.census.gov/compendia/statab/2012/tables/12s0007.pdf. Accessed September 18, 2013.
30.
NicholsH.B., Trentham-DietzA., HamptonJ.M.. From menarche to menopause: trends among US Women born from 1912 to 1969. Am J Epidemiol.2006; 164(10): 1003–1011.
31.
MahadeenA.I., HalabiJ.O., CallisterL.C.Menopause: a qualitative study of Jordanian women's perceptions. Int Nurs Rev.2008; 55(4): 427–433.
32.
FournierA., KernaleguenC., PanjoH., Clavel-ChapelonF., RingaV.Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts. Menopause.2011; 18(2): 219–223.
33.
FournierA., KernaleguenC., PanjoH., Clavel-ChapelonF., RingaV.Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts. Menopause.2011; 18(2): 219–223.
34.
SimonJ.A., Kokot-KierepaM., GoldsteinJ., NappiR.E.Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause.2013; 20(10): 1043–1048.
35.
KingsbergS.A., WysockiS., MagnusL., KrychmanM.L.Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real Women_s Views of Treatment Options for Menopausal Vaginal Changes) survey. J Sex Med.2013; 10(7): 1790–1799.
36.
SimonJ.A., Kokot-KierepaM., GoldsteinJ., NappiR.E.Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause.2013; 20(10): 1043–1048.
